Literature DB >> 19826272

Efficacy of propranolol in wound healing for hospitalized burn patients.

Ali Akbar Mohammadi1, Alireza Bakhshaeekia, Peyman Alibeigi, Mohammad Jalal Hasheminasab, Hamid Reza Tolide-ei, Ahmad Reza Tavakkolian, Mohammad Kazem Mohammadi.   

Abstract

Burn patients have the highest metabolic rate among critically ill or injured patients. Because propranolol decreases energy expenditure and muscle protein catabolism, in this study, we hypothesized that propranolol would improve healing process and decrease wound-healing time. This study was a double-blind randomized clinical trial; a total of 79 burn patients who referred to this center from January 2006 to January 2007 fulfilled the inclusion criteria. Thirty-seven patients were randomly placed in propranolol group and 42 in control group. The propranolol group received propranolol orally with the dose of 1 mg/kg/d and maximum dose of 1.98 mg/kg/d given in six divided doses. This dose was adjusted to decrease the resting heart rate by 20% from each patient's baseline value. The control group received placebo. The most common cause of burn in both groups was flame followed by flash. Patients with superficial burns in the propranolol group needed less time to heal for acceptable wound healing in superficial burns (16.13+/-7.40 days vs 21.52+/-7.94 days; P=.004). We also found that patients with deep burn injury needed less time to be ready for skin graft (28.23+/-8.43 days vs 33.46+/-9.17 days; P=.007) when compared to that of the control group. The use of propranolol decreased the size of the burn wound that finally needed skin graft. Patients in the propranolol group with an average burn size of 31.42% TBSA finally needed 13.75% of TBSA skin graft compared with that of control patients with an average burn size of 33.61% TBSA who needed 18.72% of TBSA skin graft, and patients in the control group with an average burn size of 33.61% TBSA finally needed 18.72% of TBSA skin graft (P=.006). Patients in the propranolol group had a shorter hospital stay period than the control group (30.95+/-8.44 days vs 24.41+/-8.11 days; P=.05). Administration of propranolol, improved burn wound healing, and decreased healing time and hospital stay period. The use of propranolol decreased the surface area of wounds that needed to be skin grafted.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19826272     DOI: 10.1097/BCR.0b013e3181b48600

Source DB:  PubMed          Journal:  J Burn Care Res        ISSN: 1559-047X            Impact factor:   1.845


  18 in total

1.  Role of propranolol in ulcerated haemangioma of head and neck: a prospective comparative study.

Authors:  Preeti Tiwari; Vaibhav Pandey; Ajay N Gangopadhyay; Shiv P Sharma; Dinesh K Gupta
Journal:  Oral Maxillofac Surg       Date:  2015-10-20

2.  Does beta blockade postinjury prevent bone marrow suppression?

Authors:  Alicia M Mohr; Ihab O ElHassan; Edward J Hannoush; Ziad C Sifri; Michael D Offin; Walter D Alzate; Pranela Rameshwar; David H Livingston
Journal:  J Trauma       Date:  2011-05

3.  The effectiveness and safety of beta antagonist in burned patients: A systematic review and meta-analysis.

Authors:  Jing Ma; Dingyao Hu; Zhen Feng; Jia Tang; Lanlan Guo; Yali Du; Jinxing Quan
Journal:  Int Wound J       Date:  2020-08-21       Impact factor: 3.315

Review 4.  Anabolic and anticatabolic agents used in burn care: What is known and what is yet to be learned.

Authors:  Eduardo I Gus; Shahriar Shahrokhi; Marc G Jeschke
Journal:  Burns       Date:  2019-12-15       Impact factor: 2.744

5.  Acceptation of Folk Medicine and its "secrets" in a Swiss Burn Centre.

Authors:  S Kasser; L A Applegate; N Hirt-Burri; P Jafari; A de Buys Roessingh; W Raffoul; M M Berger
Journal:  Ann Burns Fire Disasters       Date:  2019-09-30

Review 6.  Neuroendocrine regulation of inflammation.

Authors:  Caroline J Padro; Virginia M Sanders
Journal:  Semin Immunol       Date:  2014-01-31       Impact factor: 11.130

7.  The Safety and Efficacy of Propranolol in Reducing the Hypermetabolic Response in the Pediatric Burn Population.

Authors:  Sylvia Ojeda; Emily Blumenthal; Pamela Stevens; Clark R Andersen; Lucy Robles; David N Herndon; Walter J Meyer
Journal:  J Burn Care Res       Date:  2018-10-23       Impact factor: 1.845

Review 8.  Burns: an update on current pharmacotherapy.

Authors:  Yesenia Rojas; Celeste C Finnerty; Ravi S Radhakrishnan; David N Herndon
Journal:  Expert Opin Pharmacother       Date:  2012-11-02       Impact factor: 3.889

9.  β2AR antagonists and β2AR gene deletion both promote skin wound repair processes.

Authors:  Christine E Pullar; Gabrielle S Le Provost; Andrew P O'Leary; Sian E Evans; Brian S Baier; R Rivkah Isseroff
Journal:  J Invest Dermatol       Date:  2012-04-12       Impact factor: 8.551

10.  Propranolol treatment of infantile hemangioma endothelial cells: A molecular analysis.

Authors:  Jessica Stiles; Clarissa Amaya; Robert Pham; Rebecca K Rowntree; Mary Lacaze; Arlynn Mulne; Joyce Bischoff; Victor Kokta; Laura E Boucheron; Dianne C Mitchell; Brad A Bryan
Journal:  Exp Ther Med       Date:  2012-08-03       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.